Skip to content

Pioneering genomic analysis

At Congenica we’re in the business of changing lives for the better.

We are a digital health company enabling genomic medicine with the world leading Clinical Decision Support platform for research use for the rapid analysis and interpretation of genomic data.

Built on a foundation of clinical expertise, we are driven to empower healthcare professionals worldwide to transform health and wellness, improving lives by converting genomic data into actionable information.

Our platform can analyze the entire human genome, to not only find the problem but go further, collect a wealth of information, trillions of data points, then interpret and understand every detail.

Learn more about our platform

Ending diagnostic odysseys

People with genetic diseases wait an average of five years for a diagnosis. Congenica is working towards a future where diagnostic odysseys are shortened from years to days, helping to provide appropriate genomic information for more people, faster

Generating value

Congenica improves the opportunity for genomic characterization of disease. Supporting laboratories to achieve 30% higher analytical yields than averages and reduce analysis times and costs by 95%

Improving people’s lives

We support the global genomic community to achieve the best outcomes possible. Our genomic analysis solutions aid the disease characterization and research supporting people to maintain wellness and lead fuller lives


Our software is trusted by world-leading centers of excellence, diagnostic laboratories, healthcare organizations and biopharmaceutical companies.

Congenica is proud to have been selected by Genomics England as the exclusive Clinical Decision Support Platform for research use for the UK NHS Genomic Medicine Service – a groundbreaking national initiative and a world first.

Welcome Sanger Institue
UCB Pharma
Childrens Hospital of Fudan University
Digital China Health
Genomics England

We use Congenica software to significantly improve the services we provide. We cannot recommend Congenica highly enough.

Dr Sahar Mansour
Professor in Clinical Genetics, St George’s Hospital NHS

Thought Leadership

Congenica is helping to drive the conversation in genomics. Discover more about the impact of our work in our peer-reviewed publications and resource library.

Our Team

Our team includes bioinformaticians, clinical experts, software engineers and A.I. innovators.

We seek talented people who are driven to make a difference and who want to collaborate with like-minded individuals to revolutionize healthcare. If you think you’ve got what it takes and want to take your career to the next level, visit our careers page.

Congenica careers

Members of the Board

Andy Richards

Andy Richards, CBE, PhD


Andy is a well-established entrepreneur and builder of biotechnology, healthcare and diagnostic ventures. He brings a strong business focus and an in-depth knowledge of the industry and company scale up. He is currently Chairman of Arecor, Abcodia and Closed Loop Medicine and is a director of Owlstone Medical and Ieso Digital Health. He is Chairman of BBT the Babraham Research Campus and a director of Cancer Research Technology Ltd (the commercial board of Cancer Research UK). Andy is a graduate of Cambridge University with a PhD in Chemistry and a track record as a founder, active investor in and director of more than 25 innovative healthcare and life-science companies, including Vectura plc and Arakis.
David Atkins

David Atkins, PhD

Chief Executive Officer

David has over 25 years’ experience as a global leader in a broad range of diagnostics and healthcare businesses. He has held senior positions in R&D, business development, operations and sales and marketing. He has extensive commercial experience in North America, EMEA, Asia and Latin America. Prior to joining Congenica, David was CEO of Synevo, a clinical diagnostic laboratory service business operating across Germany and Eastern Europe. David also has over 20 years’ experience with Johnson & Johnson’s Medical Device and Diagnostic businesses in R&D and business development and in senior international commercial roles.
Matthew Hurles

Matthew Hurles, PhD

Scientific Director

Matt is Head of Human Genetics and Senior Group Leader at the Wellcome Trust Sanger Institute. Matt is the scientific director of the Deciphering Developmental Disorders program and was a major contributor to the UK 10K projects. He has pioneered the analysis of whole exomes in clinically relevant disorders that previously failed diagnostic methods and has led an initiative to characterize structural variation in the human genome. Matt has been awarded the Balfour Lecture by the Genetics Society and the Crick Lecture prize for accomplishments in genetics and is a Fellow of the Royal Society.
Michael Anstey

Michael Anstey, PhD

Non-Executive Director

Michael is an Investment Director at Cambridge Innovation Capital plc and is focused on Healthcare businesses. Before joining CIC he was a Principal in the Healthcare Practice Area at The Boston Consulting Group’s (BCG) Toronto office. Michael has experience in advising multinational healthcare businesses across North America, Europe, India, and Japan on a broad range of topics, including corporate strategy, sales and marketing, new launches, R&D and medical strategy, and M&A.
David Shi Congenica

David Shi

Non-Executive Director

David is the president and CEO of Digital China Health Technologies Corporation Limited. In China, he is the organizer of a national cancer database which includes information platforms in the National Cancer Center and provincial cancer hospitals, and built the National Population Macro Management Decision Model, approved by the UN. David serves as the Deputy Secretary General of the National Union for big data industry, the vice chairman of the national population medical big data Specialized Committee, and the Deputy Secretary-General of the Cancer Professional Committee on Healthcare Big Data.
Alastair Kilgour

Alastair Kilgour

Non-Executive Director

Alastair has over 30 years’ experience founding and leading various businesses and teams in broking, banking and fund management. Alastair was a Global Partner in Lazard Frere LLP. Currently he is a founder and CIO of Parkwalk Advisors, one of the biggest investors in UK University Technology Spinouts with a portfolio of over 80 companies.
Heiner Dreismann Congenica

Heiner Dreismann, PhD

Non-Executive Director

Heiner is a seasoned executive with more than 35 years of experience in the life sciences and health care industries. He was previously the President and CEO of Roche Molecular Systems, the world leader in molecular diagnostics, where he made significant contributions to the organisational and financial growth of the company’s molecular business area. Since leaving Roche Heiner has served on the board of a number of private and public biotechnology and healthcare companies in the United States, Europe and Israel.
Dr Sam Roberts Congenica

Sam Roberts, PhD

Non-Executive Director

Sam Roberts is the Managing Director of Health and Care at Legal and General, focusing on our investment strategy across the health and care sector within L&G’s Capital and Retail Retirement businesses. Prior to this Sam was Chief Executive of the Accelerated Access Collaborative, the national umbrella organisation for health innovation, hosted in NHS England and NHS Improvement.  Sam has worked in healthcare for almost 20 years, originally as a doctor before undertaking an MBA and joining McKinsey and Company, followed by a number of senior roles in the NHS. She has a research interest in using health economic models to inform health policy and commissioning and completed a DPhil in Evidence Based Medicine at the University of Oxford on this topic.

Senior Management Team

Richard Durbin

Richard Durbin, PhD

Informatics Director

Richard is a Professor in the Department of Genetics at Cambridge University and Associate Faculty of the Wellcome Sanger Institute. A pioneer in genome sequencing and bioinformatics for over 25 years, he has developed sequence data analysis tools that are now standards in the field, including the alignment software bwa and the SAM/BAM format which underpin most clinical genomic data analysis. Richard has also made significant contributions to the Ensembl resource for vertebrate genome annotation, and the TreeFam and Pfam databases and led the international 1000 Genomes Project and the UK 10K Genome Project. Richard is a Fellow of the Royal Society and a Member of EMBO.
Philip Beales

Philip Beales, PhD

Chief Medical Officer

Phil is a consultant clinical geneticist and Professor of Medical and Molecular Genetics at the UCL Institute of Child Health (ICH), an NIHR Senior Investigator, Honorary Consultant in Clinical Genetics at Great Ormond Street Hospital (GOSH) and the lead on Personalized Medicine for UCL. He is an internationally recognized expert in the genetics and pathogenesis of ciliopathies and pioneering use of next generation sequencing in mapping disease genes in this area.
Alistair Johnson

Alistair Johnson

Chief Product Officer

Alistair has over 20 years’ experience in project consultancy, product management and marketing in a range of industries including Finance, IT Security, Medicines Supply Chain Management and IT Service Management. He has worked in companies of all sizes ranging from start-ups to global enterprises including Symantec and Infor. Alistair is uniquely positioned to understand and address the technical and commercial challenges of delivering a secure, high quality system with user experience at its core.
Yvonne Larkin

Yvonne Larkin

Chief Organization Development & Talent Officer

Yvonne has over 25 years’ experience as a Human Resources leader.  She has significant talent development and change management experience, both leading and implementing business focused solutions within a range of international organizations across multiple sectors. Prior to joining Congenica, Yvonne spent 10 years with Johnson & Johnson’s Medical Device and Diagnostic businesses in EMEA where she led the creation of numerous Centers of Excellence to rapidly build expertise and capability in areas such as Commercial Excellence, Regulatory Affairs, and Market Access. Yvonne holds a BSc in Psychology and a Master of Business Studies from University College Dublin.

Rob Denison

Chief Information Officer

Rob has over 20 years experience in technology R&D and high growth software businesses. After founding and selling his own disruptive technology company he has been part of the executive team of businesses in R&D consultancy, biomedical development, and high volume webs services delivery. His experience ranges from aggressive start ups through to high growth multi billion dollar market cap organisations, where he has lead a broad range of areas of the business in CTO/CIO or COO positions. During his career he has been a member of the core team of large open source projects and has extensive experience of managing key technology partnerships.
Nick Lench

Nick Lench, PhD

Chief Scientific Officer

Prior to founding Congenica, Nick was previously Director of Genetics Services at Great Ormond Street Hospital for Children, London, with responsibility for the strategic and operational management of a genetics service that provides DNA diagnostic testing and services to a population of approximately 4.5M people. Nick is an honorary Reader at the UCL Institute of Child Health and has over 25 years’ of academic, healthcare and commercial experience in medical genetics and genomics. He was awarded a personal chair in Medical Genetics at Cardiff University in 2005 and was a founding CEO of London Genetics Ltd and Programme Director at Oxagen Ltd.

Muthu Meyyappan, PhD

Chief Commercial Officer

Muthu Meyyappan has over 20 years’ international experience building and leading diverse, global, cross-cultural teams spanning sales, marketing and customer support for companies within clinical informatics, software/database and genomic products and services markets. Prior to joining Congenica, Muthu served as Chief Commercial Officer for Variantyx and was responsible for the overall commercial strategy for their whole genome testing services for rare disease diagnosis marketed to clinicians and hospitals.  Previously, he was the Vice President of Advanced Genomics Commercial Operations for QIAGEN where he was responsible for worldwide revenue for the bioinformatics franchise. He was also Chief Business Officer for BIOBASE GmbH and held senior roles at Incyte Genomics. Muthu has many years of leadership experience in customer facing environments within the pharmaceutical, biotech, academic research and clinical sectors across NA, EMEA and APAC. Muthu holds a Bachelor’s degree in Biotechnology from the Rochester Institute of Technology, New York and a PhD in Cancer Biology from The University of Calgary, Canada.
Jonathan Day - Congenica

Jonathan Day

Senior Director - Quality and Regulatory Affairs

Jonathan has over 20 years' experience in the Life Sciences with a focus on Medical Devices including In Vitro Diagnostics and Software as a Medical Device. He has worked in both the United States and the United Kingdom starting in basic research moving to molecular biology manufacturing and on to senior global compliance and regulatory roles for large multinational organisations in addition to start-ups and SMEs. Jonathan's experience includes process excellence, regulatory strategy, remediation activities, new product introduction and submissions, in addition to building departments and compliance programmes. Jonathan holds a BSc(hons) degree in Microbiology from King's College London.

Kamraan Shariff

Chief Business Development Officer

Kamraan has over 20 years of global experience spanning corporate development, venture capital, mergers & acquisitions & investment banking.  Prior to joining Congenica, Kamraan was Head of Corporate Development at Drawbridge Health, where he was responsible for global strategic partnerships. Previously, he was a Managing Director at GE Ventures and also held senior positions within the M&A division of both GE & GE Capital across Europe and Asia. Kamraan started his career in Investment Banking, and over time assumed leadership positions across both product and coverage functions in Europe, Australia and Asia.  Kamraan received his MA in International Banking & Financial Services from the University of Reading and a BA Hons. in Economics (Industrial Studies) from the University of Leeds.

Jayesh Pankhania

Chief Financial Officer

Jayesh is a Chartered Accountant with nearly 30 years’ senior finance experience. Between 2018 and 2021 he was Chief Financial Officer of Horizon Discovery plc, a life science tools company, where he led the development of its strategy and prepared it for a Nasdaq listing. The investor outreach culminated in a successful trade sale of the business to Perkin Elmer Inc.He served as Chief Financial Officer of Xtera Limited, a provider of subsea telecoms technology, from 2017 to 2018, and HOC Group, a construction company, from 2015 to 2016. From 2011 to 2015, he was in a Deputy Chief Financial Officer role at Asia Resource Minerals plc.Jayesh holds an M.B.A. from the London Business School and a degree in Accountancy from the University of East Anglia, and qualified with PricewaterhouseCoopers.

Our quality assurance

ISO 27001 Certified British Assessment Bureau - Certificate No. 205723

Analyze and interpret genomic data rapidly, reliably and with complete confidence

Demo Congenica

pinterest Twitter Facebook email LinkedIn < Back to top